Wednesday, July 8, 2026

biotech · Fabry Disease · Bioequivalence · PLX

Protalix Biotherapeutics

Protalix Biotherapeutics clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

2 Snunit St., Science Park, POB 455, Carmiel, 2161401, IL, HACKENSACK, NJ, USA HQ
1994 Founded
197 Employees
Public company Type
PLX · NYSE Ticker
Company details
Status
Public
HQ
2 Snunit St., Science Park, POB 455, Carmiel, 2161401, IL, HACKENSACK, NJ, USA
Founded
1994
Employees
197
Programs
21
Drugs
14
Patents
22
Intelligence · Clinical Programs

Protalix Biotherapeutics projects

4 ClinicalTrials.gov programs sponsored by Protalix Biotherapeutics.

Protalix Biotherapeutics has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. PL2200 Aspirin Capsules

    Protalix BioTherapeutics

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    2 trials
  2. PRX-102

    Protalix BioTherapeutics

    Fabry Disease

    phase 3 small molecule completed

    2 trials
  3. PRX-102 (pegunigalsidase alfa)

    Protalix BioTherapeutics

    Fabry Disease

    phase 3 mab completed

    3 trials
  4. Pegunigalsidase alfa

    Protalix BioTherapeutics

    Fabry Disease

    phase 3 mab completed

    1 trial

Frequently asked questions

How many clinical projects does Protalix Biotherapeutics have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.